Tennessee Retina

Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III Study

Peter A. Campochiaro, David M. Brown, Carl C. Awh et al. · Ophthalmology · 2011 · 698 citations

Macular Edema, Ocular Disease, Vitreous Body +6

Spectrum and Susceptibilities of Microbiologic Isolates in the Endophthalmitis Vitrectomy Study

Dennis P. Han, Stephen R. Wisniewski, Louis A. Wilson et al. · American Journal of Ophthalmology · 1996 · 695 citations

Medical Microbiology, Pathogenic Microbiology, Microbial Disease +8

Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration

Allen C. Ho, Brandon Busbee, Carl D. Regillo et al. · Ophthalmology · 2014 · 577 citations

Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration

Brandon Busbee, Allen C. Ho, David M. Brown et al. · Ophthalmology · 2013 · 492 citations · Full text

The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma

Lee M. Jampol, Claudia S. Moy, Timothy G. Murray et al. · Ophthalmology · 2002 · 365 citations

Surgical Oncology, Radiation Therapy, Medicine +8